- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
--Insight Molecular Diagnostics Inc.,,, today announced participation in the upcoming Lake Street Capital Markets 10 th Annual Best Ideas Growth“ BIG10” Conference taking place September 10 th, 2026 in New York. Event: Lake Street Capital Markets 10 th Annual Best Ideas Growth“ BIG10” Conference Who: Chief Executive Officer Josh Riggs and Chief Financial Officer...
--Insight Molecular Diagnostics Inc.,,, today announced participation in the upcoming Lake Street Capital Markets 10 th Annual Best Ideas Growth“ BIG10” Conference taking place September 10 th, 2026 in New York. Event: Lake Street Capital Markets 10 th Annual Best Ideas Growth“ BIG10” Conference Who: Chief Executive Officer Josh Riggs and Chief Financial Officer...
--Insight Molecular Diagnostics Inc.,,, today announced participation in the upcoming Lake Street Capital Markets 10 th Annual Best Ideas Growth“ BIG10” Conference taking place September 10 th, 2026 in New York. Event: Lake Street Capital Markets 10 th Annual Best Ideas Growth“ BIG10” Conference Who: Chief Executive Officer Josh Riggs and Chief Financial Officer...
--Insight Molecular Diagnostics Inc.,,, today announced that it will host a virtual key opinion leader event on Monday, August 17, 2026 at 11 AM ET featuring Max Jacob Liebo, MD, who will join Nick Ioannou, MD, MHA and Josh Riggs, to discuss the Company's GraftAssure platform, which leverages digital PCR technology to deliver reliable dd-cfDNA results for...
--Insight Molecular Diagnostics Inc.,,, today announced that it will host a virtual key opinion leader event on Monday, August 17, 2026 at 11 AM ET featuring Max Jacob Liebo, MD, who will join Nick Ioannou, MD, MHA and Josh Riggs, to discuss the Company's GraftAssure platform, which leverages digital PCR technology to deliver reliable dd-cfDNA results for...
--Insight Molecular Diagnostics Inc.,,, today announced that it will host a virtual key opinion leader event on Monday, August 17, 2026 at 11 AM ET featuring Max Jacob Liebo, MD, who will join Nick Ioannou, MD, MHA and Josh Riggs, to discuss the Company's GraftAssure platform, which leverages digital PCR technology to deliver reliable dd-cfDNA results for...
In late July, the FDA completed the current phase of its substantive review of GraftAssureDx in a timely manner. We would characterize our dialogue with the FDA as routine and within the realm of our expectations. Our submission was, to our knowledge, the first-ever kitted dd-cfDNA assay to be submitted for FDA authorization.
In late July, the FDA completed the current phase of its substantive review of GraftAssureDx in a timely manner. We would characterize our dialogue with the FDA as routine and within the realm of our expectations. Our submission was, to our knowledge, the first-ever kitted dd-cfDNA assay to be submitted for FDA authorization.
In late July, the FDA completed the current phase of its substantive review of GraftAssureDx in a timely manner. We would characterize our dialogue with the FDA as routine and within the realm of our expectations. Our submission was, to our knowledge, the first-ever kitted dd-cfDNA assay to be submitted for FDA authorization.
--Insight Molecular Diagnostics Inc.,,, today announced that it will report second quarter 2026 financial results after the market closes on Monday, August 10, 2026. iMDx will host a live Zoom webinar to discuss the company's financial results at 2:00 pm PT/ 5:00 pm ET that same day. Separately, on August 11th, Chief Executive Officer Josh Riggs and Chief Financial...